multiplesclerosisnewstoday.com

multiplesclerosisnewstoday.com
Share

multiplesclerosisnewstoday.com

 •  December 4, 2017

Oral steroids may be cheaper, more convenient and less invasive alternatives than intravenous steroids in treating relapses in multiple sclerosis (MS) patients, suggests an analysis of five randomized trials. Glucocorticoids are recommended as the first line of treatment for MS relapses. Yet recent studies have shown no significant difference...

multiplesclerosisnewstoday.com

 •  October 25, 2017

Opicinumab, an investigative treatment aiming to promote remyelination in relapsing multiple sclerosis (MS) patients, will be tested in a new clinical trial — having failed at an earlier effort, but having shown promise enough in particular patients to be worth a closer look. In fact, the new AFFINITY study “is only possible because we learned a...

multiplesclerosisnewstoday.com

 •  October 3, 2017

Fast Forward, a non-profit subsidiary of the National Multiple Sclerosis Society, will give financial support to TG Therapeutics to advance TGR-1202 (umbralisib) into preclinical testing as a potential oral therapy for progressive forms of multiple sclerosis. The support, whose value was not specified, is part of a Sponsored Research Agreement...

multiplesclerosisnewstoday.com

 •  July 25, 2016

Click here to receive MS news via e-mail Sanofi Genzyme announced that the Government of Ontario has added Lemtrada (alemtuzumab) to the province’s Exceptional Access Program (EAP), opening coverage to the treatment for eligible patients with relapsing-remitting multiple sclerosis (RRMS). The program facilitates patient access to drugs not funded...

multiplesclerosisnewstoday.com

 •  October 10, 2015

The new, experimental therapy has made headlines this week after the company ... In terms of safety, Dr. Hauser reported that the most adverse events were infusion-related reactions (especially in the first infusions). In the combined cohort of patients ...